This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor:—
I want to protest officially the recognition that has been accorded Dr. Nathan S. Kline's role in the development of monoamine oxidase inhibitors, and specifically iproniazid, for the treatment of depression. This matter becomes currently urgent because of Dr. Kline's recent acceptance of the Lasker Award and the publication in The Journal of his paper "The Practical Management of Depression," presented as a result of this (190:732 [Nov 23] 1964). Neither the terms of the award nor the paper recognize that my role was primary in the development and administration of this drug for this purpose. There can be no doubt that intellectual dishonesty is involved here. I am enclosing a substantiating reprint (Saunders, J.C.: Treatment of Hospitalized Depressed and Schizophrenic Patients With Monoamine Oxidase Inhibitors: Including Reflections on Pargyline, Ann NY Acad Sci107:1081 [July 8] 1963) and a copy of my letter of
Saunders JC. Lasker Award: Priority Claim. JAMA. 1965;191(10):865. doi:10.1001/jama.1965.03080100083031